Wilson Sonsini Goodrich & Rosati represented Circle Pharma in the transaction. Circle Pharma, a clinical-stage biopharmaceutical company, announced the closing of a $90 million Series D...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Soleno Therapeutics on the offering, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. advised the underwriters. Soleno Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Amring Pharmaceuticals Inc. on the transaction, and Wilson Sonsini Goodrich & Rosati advised Visant Medical. Amring Pharmaceuticals Inc....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Cooley advised Soleno Therapeutics on the deal. Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno”) announced the pricing of the underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis LLP is representing L Catterton, and Wilson Sonsini Goodrich & Rosati is representing Thorne HealthTech, Inc. in the transaction. Thorne HealthTech, Inc. (“Thorne”)...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SetPoint Medical on the deal. SetPoint Medical, a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced an...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Enable Injections on the deal. Enable Injections, Inc., a company developing and manufacturing the enFuse platform of investigational wearable drug...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, a leader in the development of automated solutions for on-demand synthesis of genes...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented Thorne HealthTech, while Latham & Watkins represented the underwriters in the offering. Thorne HealthTech, a leader in developing innovative solutions...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Codex DNA on the deal. Codex DNA, Inc. (Nasdaq: DNAY) announced the closing of its initial public offering of 7,666,664...
You must be a Standard 1 Year member to access this content.
